

## ONLINE 19<sup>TH</sup> ESO ESMO MASTERCLASS IN CLINICAL ONCOLOGY

### Disclosure of conflict of interest

Faculty members have been asked to disclose any potential conflict of interest in relation to their participation in the above-mentioned event. Potential conflict of interest are considered any of the following:

- Any financial interest in or arrangement with a company whose products or services are discussed in the lecture or that might be considered as part of the statement process;
- Any financial interest in or arrangement with a competing company;
- Any other financial relationship, direct or indirect, or other situations that might raise the question of bias in the work presented or in the participation in the statement process, including pertinent commercial or other sources of funding for the speaker or panellist or for the associated department or organisation, personal relationships or direct academic competition.

### Block 1 – Breast Cancer

#### **F. Cardoso:**

*Recipient of honoraria or consultation fees:* Advisory Board: AstraZeneca, Astellas/Medivation, Celgen, Daiichi-Sankyo, Eisai, GE Oncology, Genentech, GlaxoSmithKline, Merck-Sharp, Merus BV, Novartis, Pfizer, Pierre-Fabre, Roche, Sanofi, Teva, Amgen, Macrogenics Mylan (IDMC), Mundipharma, Seagen

**M. Cardoso:** *No significant relationships*

**G. Curigliano:** *Module to be completed*

#### **A. Eniu:**

*Recipient of grants/research supports:* Roche, Pfizer, AstraZeneca, Celltrion, Puma

**F. Geara:** *Module to be completed*

#### **N. Harbeck:**

*Recipient of honoraria or consultation fees:* Agendia, Amgen, Astra Zeneca, BMS, Celgene, Daiichi-Sankyo, Genomic Health, Lilly, MSD, Novartis, Odonate, Pierre Fabre, Pfizer, Roche, Samsung, Sandoz/Hexal, Seattle Genetics

*Other support (please specify):* Co-Director West German Study Group (WSG)

**O. Pagani:** *Module to be completed*

**G. Pruneri:** *No significant relationships*

### Block 2 – Lung Cancer

**E. Felip:** *Module to be completed*

#### **M. Garassino:**

*Recipient of grants/research supports (Institution):* BMS, MSD, Roche, AstraZeneca, Pfizer, GSK, Novartis, Merck, Incyte, Takeda, Spectrum Pharmaceutica, Blueprint Medicine, Lilly, Ipsen, Janssen, Exelixis, Medimmune, Sanofi, Pfizer, Amgen

*Recipient of honoraria or consultation fees:* Roche, MSD Oncology, Astrazeneca, GSK, Takeda, BMS, Novartis, Tiziana Life Science, Sanofi, Celgene, Daiiki Sankyo, Inivata, Seattle Genetics, Incyte, Pfizer, Lilly, Bayer, Blueprint Medicine, Janssen

*Participation in a sponsored speakers' bureau:* AstraZeneca, Takeda, MSD, Celgene, Incyte, Roche, BMS, Otsuka, Lilly

**I. Kern:** *No significant relationships*

**F. McDonald:** *No significant relationships*

**C. Rolfo:** *Module to be completed*

#### **I. Schmitt-Opitz:**

*Recipient of grants/research supports:* Medtronic (Institutional Grant)

*Recipient of honoraria or consultation fees:* AstraZeneca

*Participation in a sponsored speakers' bureau:* Roche

*Grant for fellowship:* Roche Institutional

**R. Stahel:**

*Recipient of grants/research supports:* Financial Support of ETOP and IBCSG trials (president and scientific chair) AstraZeneca, BMS, Ipsen, MSD, Novartis, Pierre Fabre, Roche, and Pfizer.

*Recipient of honoraria or consultation fees:* Astra Zeneca, BMS, Janssen, MSD, Pfizer, Regeneron, Roche, Seattle Genetics and Takeda

*Participation in a sponsored speakers' bureau:* Amgen, Astra Zeneca, Blueprint, Eli Lilly, GSK, MSD, Novartis, Roche and Sandoz

### **Block 3 – Gastro-intestinal Cancers**

#### **A. Cervantes Ruiperez:**

*Recipient of grants/research supports:* Financial support received by my institution: Abbvie, Actuate Therapeutics, Alkermes Inc, Amgen, Astellas Pharma, Beigene, Bioncotech Therapeutics, Boehringer Ingelheim, Debiopharm International, F. Hoffmann-La Roche, FibroGen, Genmab, Janssen Research

*Recipient of honoraria or consultation fees:* MerckSerono, Amgen, Beigene, BMS

#### **S. De Dosso:**

*Recipient of honoraria or consultation fees:* Novartis, Pfizer, Ipsen, Amgen, BMS, Merck, MSD, Roche, Servier

#### **F. Lordick:**

*Recipient of grants/research supports:* BMS

*Recipient of honoraria or consultation fees:* Art Temp, Astra Zeneca, BMS, Eli Lilly, Imedex, Iomedico AG, Medscape, MedUpdate GmbH, Merck Sharp Dohme, ONO, Promedica, Roche, StreamedUp!, Taiho, Amgen, Astellas, Biontech, BMS, Eli Lilly, Merck Sharp Dohme, Merck Serono, Roche, Zymeworks

#### **D. Papamichael:**

*Recipient of grants/research supports:* MSD

*Recipient of honoraria or consultation fees:* Roche, Amgen, Merck Serono

*Participation in a sponsored speakers' bureau:* Roche, Amgen, Merck Serono

*Travel Grants:* Roche, Amgen, Merck Serono, Servier

#### **F. Penault-Llorca: Module to be completed**

#### **E. Van Cutsem:**

*Recipient of grants/research supports:* Amgen, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Ipsen, Lilly, Merck Sharp & Dohme, Merck KGaA, Novartis, Roche, Servier paid to his institution.

*Recipient of honoraria or consultation fees:* Array, Astellas, Astrazeneca, Bayer, Biocartis, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Daiichi, Halozyme, GSK, Incyte, Ipsen, Lilly, Merck Sharp & Dohme, Merck KGaA, Novartis, Pierre Fabre, Roche, Servier, Sirtex, Taiho

#### **A. Vogel:**

*Recipient of grants/research supports:* Servier

*Recipient of honoraria or consultation fees:* Roche, Bayer, Sanofi, BMS, Lilly, Novartis, Eisai, AstraZeneca, Merck, Incyte, Ipsen, Servier, PierreFabre, MSD, Janssen

*Commercial medical education provider::* Onclive

### **Block 4 – Gynaecological Cancers**

#### **N. Colombo:**

*Recipient of grants/research supports:* Roche

*Recipient of honoraria or consultation fees:* Roche, Eisai, GSK, Tesaro

#### **C. Sessa: No significant relationships**

#### **J. Vermorken:**

*Recipient of honoraria or consultation fees:* Merck-Serono, MSD, PCI Biotech, Innate Pharma, Synthon Biopharmaceuticals, WntResearch

*Participation in a sponsored speakers' bureau:* MSD, BMS, Merck-Serono, Sanofi

### **Block 5 – Genitourinary Cancers**

#### **J. Beyer: No significant relationships**

#### **K. Fizazi:**

*Participation to Advisory Boards for: Amgen, Astellas, Astrazeneca, AAA, Bayer, Clovis, Curevac, ESSA, Genentech, Janssen, MSD, Orion, Sanofi - Honoraria are provided to Gustave Roussy, my institution.*

**J. Khader:** *No significant relationships*

**H. Khaled:** *No significant relationships*

**X. Maldonado:** *No significant relationships*

**N. Mottet:**

*Recipient of honoraria or consultation fees: Roche, Pfiser*

*travel support: Roche*

## **Block 6 – Spotlights**

**M. Apro:** *No significant relationships*

**J. Arends:** *Module to be completed*

**H. Azim Jr.:**

*Employment: Innate Pharma*

**S. Bosnjak:**

*Recipient of honoraria or consultation fees: Merck, Pfizer, Helsinn Healthcare, Angelini*

**F. Boyle:** *No significant relationships*

**F. Cardoso:**

*Recipient of honoraria or consultation fees: Advisory Board: AstraZeneca, Astellas/Medivation, Celgen, Daiichi-Sankyo, Eisai, GE Oncology, Genentech, GlaxoSmithKline, Merck-Sharp, Merus BV, Novartis, Pfizer, Pierre-Fabre, Roche, Sanofi, Teva, Amgen, Macrogenics Mylan (IDMC), Mundipharma, Seagen*

**M. Garassino:**

*Recipient of grants/research supports (Institution): BMS, MSD, Roche, AstraZeneca, Pfizer, GSK, Novartis, Merck, Incyte, Takeda, Spectrum Pharmaceutica, Blueprint Medicine, Lilly, Ipsen, Janssen, Exelixis, Medimmune, Sanofi, Pfizer, Amgen*

*Recipient of honoraria or consultation fees: Roche, MSD Oncology, Astrazeneca, GSK, Takeda, BMS, Novartis, Tiziana Life Science, Sanofi, Celgene, Daiiki Sankyo, Inivata, Seattle Genetics, Incyte, Pfizer, Lilly, Bayer, Blueprint Medicine, Janssen*

*Participation in a sponsored speakers' bureau: AstraZeneca, Takeda, MSD, Celgene, Incyte, Roche, BMS, Otsuka, Lilly*

**S. Hurst Majno:** *Module to be completed*

**F. Peccatori:**

*Recipient of honoraria or consultation fees: Roche, Roche Diagnostic, Ipsen, AZ, Takeda*

*Participation in a sponsored speakers' bureau: Roche Diagnostic*

## **6-7 March 2021 – Live weekend**

**N. Thi Dan Linh :** *No significant relationships*

**B. Tombal:**

*Recipient of grants/research supports: Astellas, Amgen, Bayer, Ferring, Janssen, Myovant, Sanofi*

*Recipient of honoraria or consultation fees: Astellas, Amgen, Bayer, Ferring, Janssen, Myovant, Sanofi*

*Participation in a sponsored speakers' bureau: Astellas, Amgen, Bayer, Ferring, Janssen, Myovant, Sanofi*

**H. van Laarhoven:**

*Recipient of grants/research supports: Bayer, BMS, Celgene, Janssen, Lilly, MSD, Nordic Pharma, Philips, Roche, Servier*

*Recipient of honoraria or consultation fees: Dutch Cancer Society, Dutch Research Council, European Research Council, MaagLeverDarm Stichting, BMS, Lilly, MSD, Nordic Pharma, Novartis, Servier*

**U. Vogl:**

*Recipient of honoraria or consultation fees: Pfizer, Roche, Astellas, Janssen, Eli Lilly, Servier, MSD, Merck, Sanofi, Eisei, Healthbooks, Bayer, Novartis*